Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation
about
Pushing the envelope in the mTOR pathway: the second generation of inhibitorsVesicular Trafficking to the Immune Synapse: How to Assemble Receptor-Tailored Pathways from a Basic Building SetMitochondria, calcium, and tumor suppressor Fus1: At the crossroad of cancer, inflammation, and autoimmunitymTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and agingAutophagy is activated in systemic lupus erythematosus and required for plasmablast developmentA meta-analysis of public microarray data identifies gene regulatory pathways deregulated in peripheral blood mononuclear cells from individuals with Systemic Lupus Erythematosus compared to those withoutSystems biology of lupus: mapping the impact of genomic and environmental factors on gene expression signatures, cellular signaling, metabolic pathways, hormonal and cytokine imbalance, and selecting targets for treatment.DNA methylation modulates HRES1/p28 expression in B cells from patients with Lupus.Metabolic control of the epigenome in systemic Lupus erythematosus.Tuberous sclerosis and fulminant lupus in a young woman.Infection in systemic lupus erythematosus: friend or foe?Pathogenic mechanisms in systemic lupus erythematosus.Emerging new pathways of pathogenesis and targets for treatment in systemic lupus erythematosus and Sjogren's syndrome.Oxidative stress in the pathology and treatment of systemic lupus erythematosusHRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.T-cell and B-cell signaling biomarkers and treatment targets in lupus.Increased mitochondrial electron transport chain activity at complex I is regulated by N-acetylcysteine in lymphocytes of patients with systemic lupus erythematosusThe biology of reactive intermediates in systemic lupus erythematosus.Activation of the mTOR signaling pathway is required for asthma onset.Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.T cells as therapeutic targets in SLE.mTOR signaling: a central pathway to pathogenesis in systemic lupus erythematosus?A searchable cross-platform gene expression database reveals connections between drug treatments and disease.Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus.Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolaseAbnormalities of T cell signaling in systemic lupus erythematosus.Serine Arginine-Rich Splicing Factor 1 (SRSF1) Contributes to the Transcriptional Activation of CD3ζ in Human T Cells.Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome.T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity.Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycinN-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trialMetabolic regulation of organelle homeostasis in lupus T cellsVitamin D receptor gene is epigenetically altered and transcriptionally up-regulated in multiple sclerosisEpigenetic biomarkers of T-cells in human glioma.C9orf72 ablation causes immune dysregulation characterized by leukocyte expansion, autoantibody production, and glomerulonephropathy in mice.Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.Pharmacotherapy of systemic lupus erythematosus.Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus.Normalization of CD4+ T cell metabolism reverses lupus
P2860
Q24622222-944E3941-62B6-4842-8465-70080CB4FE1FQ26766480-B530BCC7-2F3E-4BBA-961C-7CC23AB29C56Q26798304-D98517F4-E072-4AC7-B21B-E3672B8AAB35Q28081442-2CCC4E00-805E-4DE0-B78B-6768D8DB8DA9Q28656075-9333EF1F-C17A-4A81-BCB1-B5A5C3742A72Q31142463-F333BC18-2AA1-4C8C-964D-ABE36CDB185CQ33608479-308C7A3D-5AFE-4570-A9E8-DB6565756922Q33664826-956AD96B-9189-494D-B898-027E95D2F742Q33664849-D743CF3D-59BA-4186-9E2C-E32DF706F7E5Q33664866-4A0EB430-114F-4FE7-A717-BBE54C9B9B9EQ33696879-BC9A7389-F7AC-48C6-9DDB-B6FB2DA6FACFQ33715441-54169B98-56CB-4B90-B17A-6FF3B5D41457Q33715480-5956D419-8D43-4BAB-8BB5-C6E68B0CF9AAQ33715508-5833E0F2-B9EB-4098-A8BD-25B9D02C6646Q33717763-6C680854-BFD9-47A5-ABA8-818EF9E721C3Q33718893-37096F2E-FAC2-4653-928A-E85049A04D2EQ33722895-80FA4341-DF93-43A0-8C09-93BBAD89CF44Q33802441-398291FE-4D30-495C-9CBE-50831611E0F2Q33866861-1CB9CC32-CBD6-47BC-A231-F5A3FE36F965Q34027578-FBDD3066-0174-406D-BCB6-BD792A0CF0B5Q34075552-718E9973-AAE6-417C-B25F-F934404510A6Q34107250-13873F2B-443B-4931-834A-E2D3EE8DBBB2Q34123013-C4C6F263-C386-4E0C-B952-1AC216918CA2Q34361763-16FB69F4-5DE3-4A28-8B65-89EF624A66EFQ34412837-EF99343E-5872-4B9A-9589-2C3211D838F4Q35048149-658A9958-6A31-4B32-8746-AA6583C231BEQ35092855-9DED68C4-0948-4DA0-B38F-E14B32C17C57Q35680908-DF012CF5-D578-47F4-9EA2-EB19F6D77296Q35732790-F82C07EF-A3C0-49BC-976D-C64D7A63BD21Q35836112-1983CB71-DEC2-4D0D-B0A0-CBB5D8DAB8B0Q36024179-9820B318-A7CE-49C6-B08A-697A8BA925A7Q36139749-0808B9A4-1576-4DFB-AC01-293167C5A458Q36177195-A8EF383D-43DB-4147-9065-C6CA23F18A2CQ36326855-3ACE41EC-3C25-4B0E-8CB7-AEC445A448A9Q36484129-8B253405-198F-4296-AB01-764AA28A33A6Q36691051-F09A64DB-C09A-48A5-8EA7-EE5A296507EDQ37372436-8335C7FF-CD81-4653-8AF2-6268814043BEQ37510905-278D4104-8A11-4215-B844-8D3110188FE0Q37625571-75FE6143-D7FD-4FC8-982C-32B082EF4E37Q37625717-7D9298AB-37C7-4C42-B6F5-6CB2FB2882A8
P2860
Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Activation of mammalian target ...... egulated lysosomal degradation
@ast
Activation of mammalian target ...... egulated lysosomal degradation
@en
Activation of mammalian target ...... egulated lysosomal degradation
@nl
type
label
Activation of mammalian target ...... egulated lysosomal degradation
@ast
Activation of mammalian target ...... egulated lysosomal degradation
@en
Activation of mammalian target ...... egulated lysosomal degradation
@nl
prefLabel
Activation of mammalian target ...... egulated lysosomal degradation
@ast
Activation of mammalian target ...... egulated lysosomal degradation
@en
Activation of mammalian target ...... egulated lysosomal degradation
@nl
P2093
P2860
P50
P356
P1476
Activation of mammalian target ...... egulated lysosomal degradation
@en
P2093
David R Fernandez
Eduardo Bonilla
Frank A Middleton
Mary K Crow
Paul E Phillips
Sanjay Banerjee
Tiffany Telarico
P2860
P304
P356
10.4049/JIMMUNOL.0803600
P407
P577
2009-02-01T00:00:00Z